Clinical Trial Update: An Open Label Non-Randomized Dose Escalating Trial to Assess Safety and Tolerability of Alb-Interferon Alfa 2b Every Two Weeks With Ribavirin Among HIV/HCV Coinfected Individuals [Phase 1]

View source ↗

Summary

Open-label, non-randomized Phase 1 dose-escalation trial evaluating safety and tolerability of Alb-Interferon Alfa 2b given every two weeks with ribavirin in HI…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection
• Hepatitis C

Drugs mentioned

• Alb-Interferon Alfa 2b (interferon alfa-2b)
• Ribavirin (ribavirin)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infections, HCV | Phase 1 | Status: COMPLETED